Furthermore, we define specific residues of the D2R N-terminus as targets of pathogenic autoantibodies in movement and psychiatric disorders [48], providing novel therapeutic targets for patients affected by anti-D2R antibody-associated autoimmune disorders. This evidence concerns the gene DRD2 and Autoimmunity.